This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (56)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Thrombolysis  • Cardiovascular System  • Arrhythmias  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Mhairi Copland, BSc, MBChB, MRCP; Isobel D. Walker, MD, FRCP, FRCPath; R. Campbell Tait, BSc, FRCP, MRCPath

Arch Intern Med. 2001;161:2125-2128.

Background  Warfarin sodium therapy in patients with atrial fibrillation markedly reduces the incidence of embolic stroke. However, in elderly patients warfarin therapy is often underused owing to the perceived higher risk of hemorrhagic complications.

Objectives  To assess the quality of anticoagulant control and the incidence of hemorrhagic complications and stroke in an elderly population (>75 years old) compared with a younger control group (between 60 and 69 years) and to assess the quality of anticoagulant control and incidence of hemorrhagic complications in those patients who recently commenced receiving warfarin therapy (first year of therapy).

Patients and Methods  In this retrospective follow-up study, anticoagulant control and the incidence of hemorrhagic complications and stroke were assessed in an elderly population (>75 years old) compared with a younger control group (between 60 and 69 years), all with atrial fibrillation(target international normalized ratio [INR] 2.5) and attending a hospital outpatient anticoagulant clinic.

Results  A total of 328 patients were studied over a 21-month period. There were 204 patients in the control group providing 288 patient-years of follow-up and 124 patients in the elderly group providing 170 patient-years of follow-up. The percentage of INR results in the target range was not statistically significantly different between the elderly and control groups (71.5% vs 66.1%) and the occurrences of incidences of INR greater than 7 were 4.2% in the control group and 4.7% in the elderly group (P = .96). The incidences of major hemorrhage were 2.8% per year in the elderly group and 2.9% per year in the control group (P = .96); overall incidence was 2.8% (95% confidence interval, 1.3%-4.4%). One hundred one of the 328 patients studied commenced warfarin therapy during or within 3 months of the start of the study. In this induction group, 62.1% of INRs were within the target range compared with 70.9% of INRs in patients who had been receiving warfarin therapy for more than 3 months at the start of the study (P = .002). The incidences of INR greater than 7 and major hemorrhage were 7.9% per year and 6.9% per year, respectively, in the cohort who recently began warfarin therapy compared with 3.4% per year and 1.7% per year in the group who were receiving warfarin therapy for more than 3 months.

Conclusion  While it was impossible to consider any selection bias at the level of referral to the clinic, these findings suggest that the elderly population attending our anticoagulant clinic did not have poorer anticoagulant control or an increased incidence of hemorrhage while receiving warfarin therapy.

From the Department of Haematology, North Glasgow University Hospitals National Health Service Trust, Glasgow, Scotland.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2001;161(17):2155-2156.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Warfarin Use Associates with Increased Risk for Stroke in Hemodialysis Patients with Atrial Fibrillation
Chan et al.
J. Am. Soc. Nephrol. 2009;20:2223-2233.
ABSTRACT | FULL TEXT  

Long-term Anticoagulant Therapy for Idiopathic Pulmonary Embolism in the Elderly: A Decision Analysis
Haspel et al.
Chest 2009;135:1243-1251.
ABSTRACT | FULL TEXT  

Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review
Wan et al.
Circ Cardiovasc Qual Outcomes 2008;1:84-91.
ABSTRACT | FULL TEXT  

Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world
Meiltz et al.
Europace 2008;10:674-680.
ABSTRACT | FULL TEXT  

Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Ansell et al.
Chest 2008;133:160S-198S.
ABSTRACT | FULL TEXT  

Anticoagulation for elderly patients with atrial fibrillation: not to be neglected
Taggar and Lip
Europace 2008;10:1-2.
FULL TEXT  

Surgical Treatment of Atrial Fibrillation
Voeller et al.
Card Surg Adult 2008;3:1375-1394.
FULL TEXT  

Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults
Budnitz et al.
ANN INTERN MED 2007;147:755-765.
ABSTRACT | FULL TEXT  

Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review
Hughes et al.
QJM 2007;100:599-607.
ABSTRACT | FULL TEXT  

Frequency of adverse events in patients with poor anticoagulation: a meta-analysis
Oake et al.
CMAJ 2007;176:1589-1594.
ABSTRACT | FULL TEXT  

Warfarin versus aspirin in the elderly in primary prophylaxis for atrial fibrillation
Morrison et al.
Age Ageing 2007;36:117-119.
FULL TEXT  

Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;0:ehl428v1-39.
FULL TEXT  

In defence of current treatment options: where are we now?
Voller
Eur Heart J Suppl 2005;7:E4-E9.
FULL TEXT  

Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
O'Brien and Gage
JAMA 2005;293:699-706.
ABSTRACT | FULL TEXT  

Safety of Anticoagulation Therapy in Well-informed Older Patients
Kagansky et al.
Arch Intern Med 2004;164:2044-2050.
ABSTRACT | FULL TEXT  

The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Ansell et al.
Chest 2004;126:204S-233S.
ABSTRACT | FULL TEXT  

Ximelagatran: A New Antithrombotic Option in Atrial Fibrillation
Dager
J CARDIOVASC PHARMACOL THER 2004;9:151-162.
ABSTRACT  

The Increasing Need for Anticoagulant Therapy to Prevent Stroke in Patients With Atrial Fibrillation
Ezekowitz and Falk
Mayo Clin Proc. 2004;79:904-913.
ABSTRACT  

Let's Strip the King: Eligibility Not Safety Is the Problem of Anticoagulation for Stroke Prevention in Elderly Patients With Atrial Fibrillation
Bellelli et al.
Arch Intern Med 2002;162:1067-1067.
FULL TEXT